ULTRAGENYX PHARMACEUTICAL ($RARE) posted quarterly earnings results for Q1 2026 on Tuesday, May 5th. The company reported earnings of -$1.84 per share, missing estimates of -$1.54 by $0.30. The company also reported revenue of $136,000,000, missing estimates of $161,952,336 by $-25,952,336.
Stock price change since market close: -4.0%
You can see Quiver Quantitative's $RARE stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ULTRAGENYX PHARMACEUTICAL Insider Trading Activity
ULTRAGENYX PHARMACEUTICAL insiders have traded $RARE stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.
Here’s a breakdown of recent trading of $RARE stock by insiders over the last 6 months:
- EMIL D KAKKIS (President & CEO) sold 54,404 shares for an estimated $1,240,411
- HOWARD HORN (Chief Financial Officer) has made 0 purchases and 7 sales selling 25,552 shares for an estimated $626,551.
- KARAH HERDMAN PARSCHAUER (EVP and Chief Legal Officer) has made 0 purchases and 3 sales selling 17,661 shares for an estimated $393,789.
- ERIK HARRIS (EVP & Chief Commercial Officer) sold 10,539 shares for an estimated $240,289
- JOHN RICHARD PINION (See Remarks) sold 10,029 shares for an estimated $228,661
- ERIC CROMBEZ (EVP and Chief Medical Officer) sold 7,029 shares for an estimated $160,261
- THEODORE ALAN HUIZENGA (SVP, Chief Accounting Officer) has made 0 purchases and 2 sales selling 1,717 shares for an estimated $40,131.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
ULTRAGENYX PHARMACEUTICAL Hedge Fund Activity
We have seen 165 institutional investors add shares of ULTRAGENYX PHARMACEUTICAL stock to their portfolio, and 164 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC removed 4,617,047 shares (-63.4%) from their portfolio in Q4 2025, for an estimated $106,192,081
- ASSENAGON ASSET MANAGEMENT S.A. added 2,057,951 shares (+1030.4%) to their portfolio in Q1 2026, for an estimated $43,114,073
- CITADEL ADVISORS LLC added 1,995,172 shares (+602.9%) to their portfolio in Q4 2025, for an estimated $45,888,956
- ABERDEEN GROUP PLC removed 1,431,452 shares (-97.4%) from their portfolio in Q1 2026, for an estimated $29,988,919
- RTW INVESTMENTS, LP added 1,292,737 shares (+75.7%) to their portfolio in Q4 2025, for an estimated $29,732,951
- FRAZIER LIFE SCIENCES MANAGEMENT, L.P. removed 983,715 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $22,625,445
- DEUTSCHE BANK AG\ removed 946,628 shares (-61.2%) from their portfolio in Q4 2025, for an estimated $21,772,444
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
ULTRAGENYX PHARMACEUTICAL Congressional Stock Trading
Members of Congress have traded $RARE stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $RARE stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 03/03, 02/18 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API.
ULTRAGENYX PHARMACEUTICAL Analyst Ratings
Wall Street analysts have issued reports on $RARE in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Leerink Partners issued a "Outperform" rating on 12/30/2025
- Baird issued a "Outperform" rating on 12/30/2025
- Barclays issued a "Overweight" rating on 11/24/2025
To track analyst ratings and price targets for ULTRAGENYX PHARMACEUTICAL, check out Quiver Quantitative's $RARE forecast page.
ULTRAGENYX PHARMACEUTICAL Price Targets
Multiple analysts have issued price targets for $RARE recently. We have seen 15 analysts offer price targets for $RARE in the last 6 months, with a median target of $50.0.
Here are some recent targets:
- Eliana Merle from Barclays set a target price of $43.0 on 04/29/2026
- Jeffrey Hung from Morgan Stanley set a target price of $67.0 on 04/16/2026
- Salveen Richter from Goldman Sachs set a target price of $25.0 on 03/24/2026
- Anupam Rama from JP Morgan set a target price of $74.0 on 03/12/2026
- Liisa Bayko from Evercore ISI Group set a target price of $34.0 on 02/18/2026
- Whitney Ijem from Canaccord Genuity set a target price of $79.0 on 02/18/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $50.0 on 02/17/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
